We therefore applied our platform to quantify how pMHC repertoires in melanoma change in vitro upon treatment with the CDK4/6 inhibitor, palbociclib, to better understand how CDK4/6 inhibitors could be leveraged in combination therapy regimes to improve patient outcomes. Here, CDK4 is linked to melanoma.